Skip to main content
. Author manuscript; available in PMC: 2020 Dec 17.
Published in final edited form as: Cell Signal. 2018 Sep 10;52:147–154. doi: 10.1016/j.cellsig.2018.09.005

Fig. 3: Effects of calyculin A and juglone on neuromedin N-mediated MEK dephosphorylation.

Fig. 3:

Human PASMCs were pre-treated with calyculin A (protein phosphatase type 1 and 2A inhibitor; 50 ng/ml) or juglone (peptidyl-prolyl cis/trans isomerase inhibitor; 20 μM) for 30 min, then treated with neuromedin N for 30 or 60 min. Phosphorylated MEK (pMEK) levels were monitored by Western blotting using the pMEK1/2 (S217/221) antibody. The bar graph represents means ± SEM of pMEK levels determined by densitometry expressed in arbitrary unit (au). * denotes significant difference from control at p < 0.01 (N=3).